Leveraging the MITF-dependent gene signature activated in macrophages, this work sought to address how MITF-associated enhancers are mechanistically influencing PDAC TAM functions as the tumor becomes more advanced and develops chemoresistance.
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with 90% of patients developing resistance to standard chemotherapy, such as gemcitabine/paclitaxel protein-bound (GnP). PDAC tumors are characteristically immunosuppressive and fibrotic due to programs activated in tumor-associated macrophages (TAMs) and their crosstalk with cancer-associated fibroblasts. These harsh tumor conditions contribute to the therapeutic resistance observed in patients. Preclinical studies demonstrate blockade of signaling pathways in PDAC TAMs can induce macrophage reprogramming to support antitumor response and restore chemosensitivity in tumors. Yet, their translation to the clinic has had minimal benefit in improving patient survival, particularly due to the persistence of macrophage reprogramming. If the PDAC microenvironment is to be effectively remodeled by altering TAM functionality to improve therapeutic outcomes, it is critical to understand the upstream, epigenetic regulatory mechanisms driving these different PDAC macrophages states that enable tumor progression and chemoresistance. Our work into tissue macrophages has demonstrated the transcription factor MITF strongly regulates how macrophages respond to environmental signals. Specifically, MITF binding to gene enhancers, which are DNA regions that instruct when genes are expressed, is upregulated, leading to activation of MITF-dependent genes, which are found among immunosuppressive macrophage programs. Leveraging the MITF-dependent gene signature activated in macrophages, we sought to address how MITF-associated enhancers are mechanistically influencing PDAC TAM functions as the tumor becomes more advanced and develops chemoresistance. The MITF-dependent gene signature is enriched in TAM subsets from both human PDAC and PDAC tumors from KPC (Kras +/LSL-G12D;Trp53 +/LSL-R172H;Pdx1-Cre) mice, suggesting that in part, PDAC TAMs may depend on MITF-associated enhancers. We are now processing murine parental and GnP chemotherapy-resistant tumors through a single-nuclei paired-tag omics approach to simultaneously evaluate gene expression and histone modification H3K27ac at the single cell level. This work will provide a multi-omics view of the epigenetic landscape in therapy-resistant PDAC, which will be critical to identify relevant MITF-associated enhancers that are modulated in TAMs during resistance prior to in vivo validation. Overall, our data will inform how epigenetic mechanisms are directly linked to establishing different TAM states in PDAC to facilitate novel therapeutic targets that can remodel the PDAC microenvironment and improve response to existing therapies.
Debbie K. Ledezma, Kevin Gulay, Hervé Tiriac, Andrew M. Lowy, Christopher K. Glass. Leveraging dynamic epigenetic landscapes to decode tumor-associated macrophages in pancreatic ductal adenocarcinoma [abstract]. In: Proceedings of the AACR Conference on Pancreatic Cancer: New Frontiers in Biology and Therapeutic Development; 2026 Sep 25-28; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(18_Suppl_2):Abstract nr B014.
Key lncRNAs involved in TAM polarization in PDAC are summarized, highlighting their roles in inducing the M2 phenotype and promoting PDAC progression through epigenetic modifications, ceRNA networks, and signal transduction pathways.
Hong-Shi Sun, Jia Wang, Zhong-Bo Xie et al.· Journal of physiology and bi...· 0 citations
Therapeutic N-glycan modulation is highlighted as a promising tumor microenvironment–targeted strategy for PDAC treatment by disrupting tumor–stroma communication and remodeling the tumor microenvironment by disrupting tumor–stroma communication and remodeling the tumor microenvironment.
Hui-Lan Chang, Chin-Chun Chang, Gita Riswana Nawung Rida et al.· Cancer Research· 0 citations
In pancreatic ductal adenocarcinoma (PDAC), the desmoplastic stroma and immunosuppressive tumor microenvironment (TME) present barriers to immunotherapy. Here, we show that MG53 (TRIM72) is a critical regulator of macrophage fate and anti-tumor immunity; its myeloid-specific depletion accelerates PDAC progression by lo...
Yu-Meng Pei, Meng Fang, Fan Zhang et al.· Cell Reports· 0 citations
The research focuses on leveraging genome engineering to enhance CAR T cell trafficking and function within the fibrotic tumor microenvironment (TME), and suggests that engineering adhesion dynamics can potentially surmount a central limitation of T cell accumulation in solid tumors such as PDA.
Priyanila Magesh, Christopher D. Zahm, Paolo P. Provenzano· Cancer Research· 0 citations
Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer type with a 5-year survival rate of only 13%. PDAC is unique in that up to 90% of the tumor bulk is comprised of a dense desmoplastic stroma. Enriched within PDAC’s extensive stroma are cancer-associated fibroblasts (CAFs). CAFs orchestrate tumor progression...
Marta R. Storl-Desmond, Nicole Liu, K. Forti et al.· Cancer Research· 0 citations
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most treatment-refractory malignancies, with limited and often transient benefit from chemotherapy, targeted therapy, immunotherapy, and radiotherapy. Therapeutic resistance is increasingly recognized as an ecosystem-level process arising from reciprocal intera...
Hong-Jiao Li, Jia-Ning Cui, Xin Yang et al.· Cancer Drug Resistance· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.